Opioid addiction is widespread in America, with millions of people suffering in the grips of addiction each day.  Whether it’s a prescription medication like Oxycodone or an illegal drug like heroin, addiction can take a life and turn it upside down. Addiction is a sly and cunning disease. It’s a slippery road from occasional, recreational (or prescribed) use to full-blown addiction.

However, there are effective treatment modalities available to help those struggling with opioid addiction.  One method that’s working for quite a few people is the prescription medication Suboxone.

Note: If you need to find a suboxone clinic near you, try a reliable source like https://www.workithealth.com/ for more info.

The Benefits of Suboxone

Suboxone is a drug that has been manufactured to help minimize the withdrawal effects of opioids. It’s been around since 2002 and acts much like methadone does. However, the potential for abuse is lower.

Suboxone is a maintenance drug made up of both Naloxone and Buprenorphine. Naloxone blocks the normal effects of opioids. Buprenorphine attaches to only part of the opioid receptor, limiting the usual “high” effects. Both help decrease the daunting opioid withdrawal symptoms and cravings.

Withdrawal symptoms from detoxing opioids can be intense and grueling at times, so the use of Suboxone has been received well.  Even those that must take high doses of Suboxone for treatment tend to tolerate it well. Many state that they feel “normal”, like they did before becoming addicted to opioids.

How To Choose A Suboxone Clinic

Today, there are many doctors and clinics that prescribe Suboxone for opioid addiction recovery.  It’s also covered by some insurances, which can help bring down the costs. If you’re seeking a Suboxone clinic, there are some things to look for to assure you have the best chance at recovery success.

Doctors who are registered with the DEA – Look for a clinic or provider who has undergone training to administer Suboxone as addiction recovery treatment. Also, be sure they are registered with the DEA.

Do A Local Google Search – If you’re seeking a Suboxone clinic locally, do a Google search for your area or the location you’re seeking.

Prepare Your Questions – Make a list of questions you have for the clinic. Don’t be afraid to inquire about their practice.

Here are some questions you may want them to answer:

• Do you have room for new clients or is there a waiting list?
• How soon can I get an appointment?
• What is the cost of your program?
• Do you take my insurance?
• When will I have to come in for treatments? How often?
• Do you offer counseling?
• How long have you been using Suboxone for treatment?
• Do you have any training in Suboxone as treatment?
• What does typical treatment look like in terms of dosage?

Make calls – Call those that you’re interested in and have your questions handy. Start making a list of what clinics you’re interested in. If you get the voicemail, leave pertinent information, like your full name, number, and what insurance you have (if any).

Keep in mind that the clinic’s phone staff is there to help you – not judge you.  If you run into bad attitudes or lack of help from a staff member, you may want to choose a different Suboxone clinic.

Consider Telehealth Suboxone Treatment

Some suboxone clinics are offering online treatment via telehealth options. You may have to attend your first session in person, but from there, you meet with the doctors via phone or video.

Check SAMHSA’s Buprenorphine Clinic Locator – You may find local Suboxone providers who will prescribe you Suboxone.

Suboxone Dosing

The dosing standards for drugs like Suboxone or methadone vary.  Methadone, which is administered in a clinic setting, has stricter dosing measures in place than Suboxone.

Typically, you can be prescribed Suboxone by a doctor and have that prescription filled at a pharmacy. Dosage guidelines are determined by the Substance Abuse and Mental Health Services Administration (SAMHSA) and have ultimate authority. However, the companies that make buprenorphine medication have their own dosing standards.

Medical assisted treatment (MAT) centers can prescribe Suboxone for patients. It used to be that prescribers needed DATA 2000 certification to prescribe Suboxone, but that standard is no longer in effect.  Today, doctors can simply prescribe Suboxone based on client needs.

Suboxone Dosages

When you enter medically assisted treatment, your doctor will do a full assessment to gather knowledge about drug use, history, and more. Then, they’ll create a personalized treatment plan for recovery.

Typically, those who begin taking Suboxone start with a small dosage, usually between 4mg or 8mg. It’s important to follow your doctor’s prescription precisely. Your doctor should see you within a few days of that first dose and adjust the amount based on your dose’s effectiveness and side effects. At the next visit, another adjustment may occur depending on how you’re feeling.

Suboxone does have a “ceiling effect”, which means that the medication will stop working at a particular dosage.  Most patients never reach a dosage amount higher than 20mg. You may be prescribed Suboxone in tablet form or Suboxone Film.

Once you move from the withdrawal stage to the drug maintenance stage, your doctor may lower your dosage gradually. Of course, Suboxone is not a one-size-fits-all solution to opioid addiction. Combining other forms of therapy can help, such as counseling, outpatient treatment, or a support group.

Should you need a Suboxone clinic, do your homework and choose the best one for you. Seek out a physician that is familiar with Suboxone treatment.

You deserve a life that is free from addiction. Take your first step today in getting your life back and creating a life that you love.

Push Technology, the pioneer and leader in real-time data streaming and messaging solutions, announced a partnership with Innova Solutions, an ACS Solutions company, specializing in global information technology services. Innova Solutions provides a wide range of digital transformation services for their clients including: data lifecycle services such as analytics and Robotic Process Automation (RPA); real-time application development, and cloud enablement and migration.

Push and Innova will collaborate to deliver industry specific real-time solutions with a focus on helping financial services and healthcare organizations reduce operational complexity and cost, increase scale of real-time data delivery of their systems by orders of magnitude to meet market demands, and assure data access control and security.

In the financial services and healthcare markets Kafka adoption and usage is high.  Therefore, it is particularly important that Innova’s data technology partner can easily handle integration with customers’ in-place Kafka brokers.   Push Technology’s Diffusion Intelligent Data Mesh provides seamless integration with Kafka brokers by automatically mapping Kafka message types to JSON, allowing web, mobile, and IoT clients to securely consume data that is stored as rich data structures within Kafka.  Diffusion’s powerful Kafka data integration and optimization across the Internet will, for example, facilitate efficient and reliable real-time data delivery for Innova’s financial services trading and healthcare payment service systems.

Rajkumar Velagapudi, founder and president of Innova Solutions, said: “In terms of client engagements, the main challenges we face are assuring reliability of real-time data delivery, very large scalability, and data security, particularly in relation to cloud deployments. These are industry priorities. The Diffusion Intelligent Data Mesh is a robust solution for our customers – it is purpose-built to handle the unique, real-time data challenges and interactions among data sources, applications, users, and devices. For our clients, Diffusion will deliver real-time intelligence and control at the network edge.”

He continued, “The partnership with Push will enable us to increase revenues, expand our pipeline, and enhance our real-time application development credibility with new and existing clients.”

Sean Bowen, CEO of Push Technology, said: “Our partnership with Innova Solutions will accelerate applying the unique capabilities of Diffusion in support of digital transformation in finance, healthcare and other industries.  Our Diffusion Intelligent Data Mesh is secure, highly scalable, and enterprise-hardened to meet the real-time data challenges organizations face today. This is important for organizations with on-premise systems as well as for those who want to reap the benefits of the cloud.”

About Push Technology

Push Technology pioneered and leads the market in real-time data streaming and messaging solutions that power mission-critical business applications worldwide. The Diffusion Intelligent Data Mesh delivers centralized data management, optimization, and integration to simplify application development, reduce infrastructure requirements, and speed time-to-market.  Leading brands, across industries including: financial services, transportation, energy, retail, healthcare, eGaming, and Internet-of-Things companies, use Diffusion to fuel revenue growth, customer engagement, and business operations. Diffusion is available on-premise, in-the-cloud, or in hybrid configurations, to fit the specific business, regulatory, and infrastructure requirements of the applications operating in today’s everything connected world.

About Innova Solutions

Innova Solutions (an ACS Solutions company) is a global information technology services firm combining a global reach with a local touch. Headquartered in Santa Clara, California, Innova employs more than 1,700 technology professionals worldwide, with field offices in New York, Chennai, Bangalore, Hyderabad, Pune, and Taipei. From Cloud Transformation to Data Services to Managed IT Operations, Innova provides a broad array of proven, tested, cost-effective and enterprise-scale technologies and services that leverage latest technology and delivery models to deliver high value in the cloud, in the data center, and across complex interconnected environments.

The Texas Heart Institute (THI) was awarded a prestigious four-year R01 grant from the National Heart, Lung, and Blood Institute, part of the National Institutes of Health (NIH) to develop the first fully implantable circulatory support device small enough for infants and small children. The device will be designed to stop the progression of advanced heart failure in pediatric patients, with the hope of enabling young children to live a near-normal life.

The work will be led by O.H. Frazier, MD, and co-investigators of the THI Cullen Cardiovascular Research Laboratories and will be a collaborative effort between THI and international consultants in Australia, Japan, and the United Kingdom. This pediatric-focused grant is a major accomplishment for Dr. Frazier and his team that builds upon decades of research work performed at THI. Dr. Frazier will oversee the device development and all preclinical studies and will lead a team of investigators that includes THI’s Dr. Yaxin Wang and Dr. Abdelmotagaly Elgalad, as well as some of the brightest consultants in the field such as Dr. Charles D. Fraser, Jr. (USA), Dr. Katharine Fraser (UK), Dr. Nobuyuki Kurita (Japan), Dr. Chris Chan Hoi Houng (Australia), and Dr. Peter Alex Smith (USA).

Dr. O.H. Frazier, the study’s Principal Investigator, is truly a living legend and is celebrated for his significant contributions to the field of mechanical circulatory support and for pioneering life-saving treatments for patients with heart failure. He has performed more than 1,200 heart transplants and has implanted more than 900 left ventricular assist devices (LVADs)—more than any other surgeon in the world. Today, Dr. Frazier serves as the Director of the Cullen Cardiovascular Research Laboratories at THI and is a Professor of Surgery at Baylor College of Medicine. For more than 30 years, Dr. Frazier has been dedicated to improving the treatment of severe heart failure and advancing heart transplantation and artificial devices that substitute or assist with the pumping action of the human heart. Dr. Frazier served on the NIH National Heart Lung and Blood Institute Advisory Committee and chaired the original committee that initiated the first federal allocation system for the distribution of hearts for transplantation. As a result of his work, Dr. Frazier is one of the top transplantation and mechanical circulatory support surgeons in the world. Throughout the 1970s and 80s, Dr. Frazier conducted experimental work toward developing an implantable LVAD. In 2011, he implanted the first successful continuous-flow total artificial heart by using two second-generation HeartMate II LVADs to replace a patient’s failing heart.

Dr. Charles D. Fraser, Jr., a consultant for the study, is one of the world’s leading pediatric and congenital heart surgeons and is a Trustee to the Board of THI. He has fostered the development of nationally and internationally recognized pediatric heart and lung transplant and mechanical circulatory support programs, and he is a pioneer of lifesaving first-in-human procedures and devices. Dr. Fraser serves as the Chief of Pediatric and Congenital Cardiothoracic Surgery at Dell Children’s Medical Center of Central Texas and holds faculty appointments at Dell Medical School at The University of Texas at Austin, where he is a tenured professor in the Departments of Surgery and Perioperative Care and Pediatrics. Dr. Fraser’s leadership has impacted more than 16,000 children and adults in need of congenital cardiac repairs and related surgeries. He has improved the surgical care of these patients with complex neonatal repairs, cardiac surgery, valve repair, and treatments for adults with congenital heart disease. In addition, he has been instrumental in the training of a new generation of surgeons.

“In the pediatric world, device development still lags behind that for adults. The reality is that children have a paucity of devices, aside from one pulsatile heart, the Berlin Heart. What we are left to do is to take adult devices and use them off-label, which is suboptimal,” says Dr. Fraser.

Dr. Yaxin Wang, who brings expertise in the hemodynamic evaluation of LVADs, is a research scientist in the Center for Preclinical Surgical and Interventional Research at THI. After earning a Master of Science degree in biomedical engineering at Rheinisch-Westfälische Technische Hochschule, Germany, Dr. Wang performed her Ph.D. studies at the University of Cambridge, United Kingdom. Her doctoral research was primarily focused on the in vitro hydraulic and hemodynamic evaluation of existing LVADs. Dr. Wang’s broad research interests are in cardiovascular device design and engineering. She has gained specific expertise with using mock circulatory loops (MCLs) to analyze the hemodynamic effects of LVADs on the human cardiovascular system and has used them to design and evaluate partial-support LVADs for the treatment of early-stage heart failure. A primary focus of her research has been developing an MCL that can accurately simulate the human left ventricle with appropriate physiologic responses. In the process of developing an LVAD, it is important to evaluate its hemodynamic effect on the compromised left ventricle. The MCL is widely accepted as an in vitro test platform for evaluating LVADs across a wide range of conditions to examine how the device and the cardiovascular system interact.

Although formal pump development is a well-established field with a history that dates back decades, the implementation of smaller pumps in complex fluids such as blood requires more thorough methods to adequately assess the pump performance and hemocompatibility of these new devices. Dr. Wang is an expert in this area and will carry out the hemodynamic evaluation of the pediatric NeoVAD, that will be developed with this grant. “We believe the NeoVAD will give neonates and young children another chance before they get their donor’s heart,” says Dr. Wang.

The following investigators will also play critical roles in this project.

Dr. Abdelmotagaly Elgalad will provide specialized expertise in developing a large-preclinical model for the in vivo investigation of the NeoVAD. Dr. Elgalad is the Assistant Director at the Center for Preclinical Surgical and Interventional Research at THI.

Dr. Katharine Fraser will use computational fluid dynamics to analyze the blood flow field in different design iterations of the NeoVAD and will use numerical models to estimate the potential damage to the blood and assist with optimizing the design to reduce this damage. Dr. Fraser is an Assistant Professor in the Department of Mechanical Engineering at the University of Bath, United Kingdom.

Dr. Nobuyuki Kurita will develop the magnetic levitation system for the NeoVAD, which is the core technology of the ultra-compact artificial heart. Mr. Kurita is an Associate Professor in the Department of Electronics and Informatics at Gunma University, Japan.

Dr. Chris Chan Hoi Houng will apply the latest hemocompatibility bioassays to the novel pump. Houng is a Senior Research Fellow in the Department of Engineering and Built Environment at Griffith University, Gold Coast, and is head of BioRheology Lab, Critical Care Research Group (CCRG) in Brisbane, Australia. CCRG is a world leader in the field of critical care research and biomedical engineering, with a focus on developing mechanical circulatory support technologies that improve outcomes for critically ill patients.

Dr. Peter Alex Smith will use his engineering experience in fluid dynamics and hydraulic design to conduct an experimental evaluation of the impeller performance of the NeoVAD. Dr. Smith is Chief Technology Officer of TYBR Health, a postoperative adhesion prevention company borne from the Biodesign Fellowship program at the Texas Medical Center. Dr. Smith has extensive experience with medical device development.

Beginning with the first implantation of an artificial heart by Dr. Cooley in 1969, THI has worked to address significant research gaps and to secure critical funding from the National Heart, Lung, and Blood Institute (NHLBI) and other government and non-government sources. The NHLBI has been a substantial source of support for THI, stimulating discoveries and enabling the translation of these discoveries into clinical practice. Although THI has a long track record of receiving funding awards from the NIH that have resulted in successful device development and productive partnerships with industry, this award is the first instance of funding granted for the purpose of developing a continuous-flow pump.

The research reported in this publication is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number 1R01HL153538-01: “Development of a Fully Implantable Ventricular Assist Device for Neonates and Children with Heart Failure with Magnetic Levitation to Improve Hemocompatibility.” The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

About Texas Heart Institute

The Texas Heart Institute (THI), founded in 1962 by world-renowned cardiovascular surgeon Dr. Denton A. Cooley, is a nonprofit organization dedicated to reducing the devastating toll of cardiovascular disease through innovative and progressive programs in research, education, and improved patient care.

Some men struggle with erectile dysfunction (ED) as they age. But aside from aging, ED can also be caused by a variety of other reasons such as underlying health conditions or stress. Men who are suffering from this condition tend to avoid a consultation with a doctor and it is in these instances wherein they turn to ED pills such as Bluechew. However, the question remains as to how good Bluechew is. In line with this, below is a quick review of the pill based on several factors listed below.

Purchase

The great thing about Bluechew is that you can have it shipped straight to you in a discreet manner. This means that you no longer have to go for a visit to the clinic to get a prescription for this ED pill. Because of this, several Bluechew reviews rate this chewable pill with five stars because it saves men the trouble of having to wait in line for a consultation before heading over to a pharmacy for the medication. More often than not, this is not a good experience. To be on the safe side though, ensure that you don’t have any serious medical conditions before trying out Bluechew which you can effortlessly and discreetly purchase.

Packaging

Another plus for Bluechew is its packaging because each pill comes in individual packs that you can easily put inside your wallet or your pocket. This proves to be beneficial as you can easily take in the pill when you need it. The sachets also keep the pill in good condition and it doesn’t come with an ED label, except for the Bluechew logo, making it quite discreet. The only downside is that this kind of packaging is not that eco-friendly compared to the packaging of bottled ED pills.

Variety

With Bluechew, you can choose between two varieties namely the Sildenafil and the Tadalafil. The former is the active ingredient that you can find in Viagra while the latter is the active ingredient that you can find in Cialis. Sildenafil is best for younger men with performance anxiety or those who want to boost their libido. It is also good for men who are suffering from temporary ED due to stress. This is also perfect for those who are new to taking ED pills and are worried about side effects. On the contrary, Tadalafil is best for men who are over 45 years old and who need more potent ED medication. Perhaps the most notable difference between the two is the duration of their effect wherein Sildenafil only lasts for 4-6 hours while Tadalafil’s effect can last up to 36 hours.

Sildenafil also guarantees an immediate erection while Tadalafil makes it easy for you to have an erection within a 24-36 window. Because of the variety of pills that you can choose from, you will be able to purchase one that fits your needs.

Effect

Bluechew is one of the pioneer ED pills in the market that is chewable, which brings forth a faster effect compared to swallowed medicine. This means that you don’t need to wait for the pill to reach your stomach before you feel its effects. Thereby, if you are in a rush to get some action, then you only need to wait about 15-20 minutes before you’re ready. Chewable pills are also perfect for those who have trouble swallowing tablets because of their gag reflex.

Reputation

The medical professionals prescribing Bluechew are all licensed physicians. But this is according to their official site, which is why it can be quite difficult to verify this information. Nevertheless, if you decide to take their word for it, then you must also be open to certain side effects, which are usually very unlikely, but it can still happen. For this reason, if you have any uncertainties, make sure that you consult with your doctor before taking the pill. On the other hand, if you have any concerns about their product, you will be able to get in touch with their customer service round the clock.

To wrap things up, there is nothing wrong with trying out ED pills. to address your condition. Nevertheless, it is still best to consult with a doctor about this to ensure that you will get the most effective but safe treatment. In the end, what matters is that you bring your manhood back to life not only for yourself but to preserve your relationship with your partner as well. After all, what happens under the sheets is just as important as your emotional connection with each other.

Centene Corporation announced it is working with Samsung Electronics America to expand access to telehealth for individuals living in rural and underserved communities. The initiative will supply providers with Samsung Galaxy A10e smartphones to disseminate to patients who would not otherwise have the ability to receive their healthcare virtually. Additionally, some providers will receive Samsung Galaxy tablets to use to conduct telehealth visits.

With this initiative, Centene and Samsung will deploy 13,000 Galaxy A10e smartphones, with 90 days of free wireless service, to approximately 200 federally qualified health centers (FQHCs), other providers and community support organizations throughout Centene’s markets, with a particular focus on rural and underserved areas. The providers and organizations will then determine which of their patients need the devices and distribute them accordingly.

Centene previously announced the creation of a Medicaid Telehealth Partnership with the National Association of Community Health Centers (NACHC) to help FQHCs quickly ramp-up their capacity to provide telehealth solutions to meet the needs created by the COVID-19 crisis.

As of mid-July, a CDC survey found that 44.4 percent of respondents reported delaying or not receiving care for various reasons, including concerns and challenges around COVID-19. Meanwhile, prior to the COVID-19 outbreak, rural residents already exhibited higher mortality rates and higher incidences of preventable inpatient and emergency room admissions than their counterparts in urban areas.

“We are committed to ensuring our members, providers and communities have access to the care they need, especially during this unprecedented time when patients might not feel safe going to the doctor in person or have reliable means to get there,” said Michael F. Neidorff, Chairman, President and CEO of Centene. “We believe telehealth solutions will significantly improve access to care and are pleased that we can help give providers the telehealth infrastructure they need to take care of underserved communities across the nation.”

The global pandemic has prompted the rapid acceleration of digital transformation, especially in healthcare,” said Taher Behbehani, General Manager and Head of Mobile B2B Business at Samsung Electronics America. “With one billion telehealth visits expected to take place by the end of 2020, Samsung is committed to supporting healthcare institutions with solutions that transform the patient experience remotely and help doctors and nurses work more efficiently. We’re thrilled to partner with Centene on this effort to create critical healthcare access for vulnerable patients during this uncertain time.”

About Centene Corporation

Centene Corporation, a Fortune 50 company, is a leading multi-national healthcare enterprise that is committed to helping people live healthier lives. The Company takes a local approach – with local brands and local teams – to provide fully integrated, high-quality, and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Centene offers affordable and high-quality products to nearly 1 in 15 individuals across the nation, including Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace, the TRICARE program, and individuals in correctional facilities. The Company also serves several international markets, and contracts with other healthcare and commercial organizations to provide a variety of specialty services focused on treating the whole person. Centene focuses on long-term growth and the development of its people, systems and capabilities so that it can better serve its members, providers, local communities, and government partners.

Centene uses its investor relations website to publish important information about the company, including information that may be deemed material to investors.

The agreement will highlight a physical hub, a specialized team, leading start-ups, comprehensive data infrastructure and an expansive network.

Healthcare innovation will soon be accelerated in the United Arab Emirates, after the country’s APEX National Investment signed a memorandum of understanding with Sheba Medical Center to promote a range of healthcare solutions in the region.

“We believe that the agreement between APEX National Investment and Sheba will change the dynamics of healthcare and innovation in the UAE and act as a harbinger of ‘peace and prosperity’ in the Gulf region and beyond, where hope knows no boundaries,” said Prof. Yitshak Kreiss, director-general of Sheba.

“We see this as a bridge for peace not only between Israel and the UAE,” Eyal Zimlichman, deputy director-general, chief medical officer and chief innovation officer at Sheba, told The Jerusalem Post. “This will be an ‘ARC’ that will serve not only the UAE but the whole region, and the hope is that this opens up new avenues to work with our neighbors that we don’t currently have ties with.”

“It is fitting that the first significant partnership between Israel and the UAE is in healthcare,” US Ambassador to Israel David Friedman said. “The Abraham Accords are already making the Middle East safer and more prosperous.”

The agreement, known as the “ARC Gulf” initiative, will highlight a physical hub, a specialized team, leading start-ups, comprehensive data infrastructure and an expansive network needed to springboard innovation in the region and beyond.

APEX and Sheba will cooperate on key medical challenges, including battling COVID-19, but also artificial intelligence, telemedicine, precision medicine, virtual and augmented reality and digital innovations in surgery and rehabilitation. Zimlichman said there is also discussion of a joint investment fund.

The agreement will be accelerated by collaborating with the healthcare authorities within the UAE’s public and private sectors, and by implementing Sheba’s ARC concept.

Sheba’s ARC ecosystem brings together clinicians, start-ups, industry, leading medical centers and national partners in Israel to transform healthcare.

“The agreement reflects the extent of the two countries’ interest in developing and reaching the highest standards in the field of health to serve the people in the region, as well as an extension of both states’ efforts in developing cutting-edge innovation in the medical field,” said Khalifa Khoury, APEX national investment chairman.

“Seeing the life science sectors from these two countries come together with speed and professionalism is a great indicator of the potential of the Abraham Accord,” said Avi Berkowitz, White House special representative for international negotiations.

Kreiss said the agreement with APEX represents the culmination of the hospital’s yearlong effort with the Gulf.

IN JUNE 2019, Kreiss attended the “Peace for Prosperity” workshop in Bahrain and shared pictures on Facebook of his visit with Bahrain’s former ambassador to the United States Houda Nonoo. According to the post, “they discussed how healthcare and medical innovation can spur economic growth for the Middle East and Gulf regions.”

“The conference was called Peace for Prosperity,” Kreiss said. “I understood immediately that healthcare – medicine – is one of the best vehicles for prosperity in the region. It has no barriers at all. You can build a true bridge.”

Since that summer, Kreiss said, he has been talking with anyone who is willing – including the UAE. He said Sheba is working with other Gulf states, too, but he could not share details yet or it could “endanger the relationships.”

An official signing ceremony will take place between September 21 and 24 in Abu Dhabi, which will be attended by the UAE’s health minister and members of the royal family.

Yoel Hareven, Sheba’s director of the international division, told the Post that the Apex-Sheba agreement “accelerated very, very fast.” He said there had been preliminary negotiations with the UAE in 2018 and 2019, but nothing particular until after the announcement by the countries’ leaders that there was a goal to normalize ties.

The announcement was made one week, and by the next, Hareven said, representatives from the UAE had contacted him. “They were waiting for the opportunity,” he said, noting that the final contract is meant to be signed within the next six months, if not before.
“The Gulf states are really a point of entry for Israel to the Arab states that are not radical,” Hareven said, explaining that it is likely that there will be representation in the ARC from Egypt, Morocco, Libya, Algeria, Tunisia, Bahrain and Oman.

“I think it is so important to have a bridge there,” he continued. “Right now, our aim is to build one ARC in the Emirates and that it will be an ARC for the area. But we never say never. If there was a suggestion to build an ARC in Morocco, we would be happy to do it.”